Tempero Bio Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $77M

  • Investors
  • 7

Tempero Bio General Information

Description

Developer of transformative therapies designed for treating and preventing substance use disorders. The company offers a potent, orally available metabotropic glutamate receptor negative allosteric modulator (NAM) that regulates neural signaling, with investigations targeting conditions such as cocaine and alcohol use disorders, enabling doctors to support patients in overcoming dependencies and enhancing overall health outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1111 Broadway
  • Suite 1300
  • Oakland, CA 94607
  • United States
+1 (510)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1111 Broadway
  • Suite 1300
  • Oakland, CA 94607
  • United States
+1 (510)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tempero Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 05-Nov-2025 $77M Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A2) 02-Nov-2020 Completed Pre-Clinical Trials
2. Early Stage VC (Series A1) $5.53M $5.53M Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view Tempero Bio’s complete valuation and funding history, request access »

Tempero Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series B-2
Series B-1
Series A-3
Series A-2 1,999,000 $0.000100 2% $3.07 $3.07 1x $3.07 5.87%
Series A-1 6,500,000 $0.000100 2% $3.08 $3.08 1x $3.08 19.08%
To view Tempero Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Tempero Bio Patents

Tempero Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2025521621-A Methods for treating substance use disorders using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 negative allosteric modulators - patents.com Pending 24-Jun-2022
AU-2023289075-A1 Methods of treating substance use disorder with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 negative allosteric modulators Inactive 24-Jun-2022
EP-4543453-A1 Methods of treating substance use disorder with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 negative allosteric modulators Inactive 24-Jun-2022
EP-4543453-A4 Methods of treating substance use disorder with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 negative allosteric modulators Inactive 24-Jun-2022
US-20250249001-A1 Methods of treating substance use disorder with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 negative allosteric modulators Inactive 24-Jun-2022 A61K31/506
To view Tempero Bio’s complete patent history, request access »

Tempero Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tempero Bio Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
8VC Venture Capital Minority
Khosla Ventures Venture Capital Minority
Palo Santo Venture Capital Minority
SymBiosis (Bentonville) Venture Capital Minority
Aditum Bio Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Tempero Bio FAQs

  • When was Tempero Bio founded?

    Tempero Bio was founded in 2020.

  • Where is Tempero Bio headquartered?

    Tempero Bio is headquartered in Oakland, CA.

  • What is the size of Tempero Bio?

    Tempero Bio has 10 total employees.

  • What industry is Tempero Bio in?

    Tempero Bio’s primary industry is Drug Discovery.

  • Is Tempero Bio a private or public company?

    Tempero Bio is a Private company.

  • What is the current valuation of Tempero Bio?

    The current valuation of Tempero Bio is .

  • What is Tempero Bio’s current revenue?

    The current revenue for Tempero Bio is .

  • How much funding has Tempero Bio raised over time?

    Tempero Bio has raised $88.6M.

  • Who are Tempero Bio’s investors?

    8VC, Khosla Ventures, Palo Santo, SymBiosis (Bentonville), and Aditum Bio are 5 of 7 investors who have invested in Tempero Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process